Company news
Oncozenge Ab (OMXSTO:ONCOZ) news
Oncozenge Ab news releases on 6ix. Latest, Sep 23, 2026: OncoZenge: Rights issue concludes at ~92% subscription
Press releases & updates
OncoZenge: Rights issue concludes at ~92% subscription
September 23, 2026
OncoZenge announces the final outcome of the rights issue
September 22, 2026
OncoZenge announces the preliminary outcome of the rights issue
September 18, 2026
OncoZenge: New patent application targets dental and oral pain
September 11, 2026
OncoZenge Files New Patent Application to Expand BupiZenge™ IP Protection into Dental and Oral Medical Use
September 11, 2026
OncoZenge AB advances global patent strategy for BupiZenge™ with filings in 17 markets
August 31, 2026
OncoZenge secures bridge financing of SEK 2.0 million ahead of rights issue
August 28, 2026
OncoZenge: SEK33.3m Rights issue announced
August 26, 2026
OncoZenge resolves on a rights issue of approximately SEK 33.3 million and publishes preliminary financial information for the second quarter of 2026
August 25, 2026
OncoZenge completes partial registration of shares in directed share issue
August 21, 2026
OncoZenge Extends the Payment Deadline for Remaining Subscription Proceeds
August 14, 2026
OncoZenge has received partial payment of SEK 5.0 million for subscription proceeds in directed share issue and extends payment deadline
July 10, 2026
OncoZenge AB Announces Enrollment of First Patient in Pivotal Phase III BEAM-Pain Trial of BupiZenge™
July 7, 2026
OncoZenge AB Appoints Linda Nord as Head of Regulatory Affairs
June 3, 2026
OncoZenge Receives CTA Approval Milestone Payment From Molteni Farmaceutici
June 2, 2026
BULLETIN FROM THE ANNUAL GENERAL MEETING OF ONCOZENGE
May 27, 2026
OncoZenge (Q1 Review): Final CTA approval received, initiating pivotal study
May 26, 2026
OncoZenge Receives European Regulatory Approval to Start Pivotal Phase III Trial of BupiZenge™
May 26, 2026
OncoZenge enters into a loan agreement of SEK 2 million with Linc AB
May 22, 2026
OncoZenge Provides Regulatory Update on BupiZenge™ Phase III Trial
May 19, 2026
OncoZenge AB Publishes Annual Report for 2025
April 30, 2026
OncoZenge Receives Conditional Acceptance for the Clinical Phase III Trial (‘BEAM-Pain’) of BupiZenge™ from European Authorities
April 28, 2026
Notice of the Annual General Meeting of OncoZenge AB (publ)
April 24, 2026
OncoZenge Confirms Submission of Responses to EMA on the BupiZenge™ Phase III Trial (BZ003)
April 2, 2026
OncoZenge Reports Positive Stability Results for BupiZenge™ as Key Enabler for the Upcoming Phase III Trial
April 1, 2026
OncoZenge AB Year-end Report January 1 – December 31, 2025
February 26, 2026
OncoZenge Receives Investment Capital From Yangtian Bio-Pharmaceutical
February 12, 2026
OncoZenge AB Appoints Dr. Marie-Louise Fjällskog as Chief Medical Officer
February 2, 2026
OncoZenge AB Reports Positive Initial Stability Results for the BupiZenge™ Technology Batch, Advancing Toward Clinical Trials
January 30, 2026
OncoZenge enters into convertible loan agreement with Linc AB and gives an update on the payment of subscription proceeds
January 22, 2026
OncoZenge advances BupiZenge with CTA submission and 9,1 MSEK funding tranche
December 19, 2025
OncoZenge resolves on a directed share issue to Sichuan Yangtian Bio-Pharmaceutical pursuant to existing investment agreement
December 19, 2025
OncoZenge Submits Clinical Trial Application for Pivotal Phase III Trial (BZ003) of BupiZenge™
December 18, 2025
OncoZenge AB Enters into Collaboration with UCLA for Patient Engagement Study on BupiZenge™
September 17, 2025